Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762981 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT02762981 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 85 participants.
The verdict
NCT02762981, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.
Interventions
- DRUG Relacorilant with nab-paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2020-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762981
The ClinicalTrials.gov registry entry for NCT02762981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Relacorilant with nab-paclitaxel is the first listed.
NCT02762981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02762981 about?
NCT02762981 is a clinical study titled "Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors". The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. ...
What is the current status of trial NCT02762981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2016-05-23. Estimated completion is 2020-09-12.
What interventions are being tested in trial NCT02762981?
The interventions under investigation include: Relacorilant with nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02762981?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.